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ABSTRACT  
Combination of cytotoxic therapy with emerging DNA damage response inhibitors 
(DDRi) has been limited by tolerability issues. However, the goal of most combination 
trials has been to administer DDRi with standard-of-care doses of chemotherapy. We 
hypothesised that mechanism-guided treatment scheduling could reduce the incidence 
of dose-limiting toxicities and enable tolerable multitherapeutic regimens. Integrative 
analyses of mathematical modelling and single-cell assays distinguished the synergy 
kinetics of WEE1i from CHK1i by potency, spatiotemporal perturbation, and mitotic 
effects when combined with gemcitabine. These divergent properties collectively 
supported a triple-agent strategy, whereby a pulse of gemcitabine and CHK1i followed 
by WEE1i durably suppressed tumour cell growth. In xenografts, CHK1i exaggerated 
replication stress without mitotic CDK hyperactivation, enriching a geminin-positive 
subpopulation and intratumoral gemcitabine metabolite. Without overt toxicity, addition 
of WEE1i to low-dose gemcitabine and CHK1i was most effective in tumour control 
compared to single and double agents. Overall, our work provides quantitative insights 
into the mechanisms of DDRi chemosensitisation, leading to the rational development of 
a tolerable multitherapeutic regimen. 
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INTRODUCTION 
Cancer cells contend with challenging intracellular stress arising from dysfunctional cell 
cycle regulations (1). In many tumour subtypes, defects in the p53 gene as well as in 
associated signalling pathways impair core processes of the DNA damage response 
(DDR) programme. This scenario renders cancer cells susceptible to exogenous 5 
damage, a concept that underpins the use of current chemotherapy. However, because 
of their non-selective mechanisms of action, many cytotoxic agents operate within a 
narrow therapeutic window. A strategy to redress this clinical issue is through the 
development of targeted agents that exploit cancer-specific cell cycle functions (2).  
The cell cycle is regulated by a network of diverse, partly overlapping and in some 10 
cases redundant checkpoints. These fidelity-monitoring checkpoints are invoked upon 
DNA damage to promote cell cycle delay and DNA repair. In human cells, the G2-M 
checkpoint governs mitotic entry, a transition highly dependent on CDK1. A major 
negative regulator of CDK1 is WEE1 kinase. Under physiological condition, WEE1 
activity rises during S and G2 phases in tandem with its protein expression (3). At 15 
mitotic onset, WEE1 is inhibited by CDK1 in a double-negative feedback loop to allow 
for the activation of the latter. Conversely, during genomic crisis, WEE1 phosphorylates 
CDK1 at its inhibitory residue tyrosine 15, deactivating it and thereby preventing mitotic 
entry (4). Apart from its involvement in G2-M transition, more recent studies have begun 
to clarify the functions of WEE1 during S phase. Similar to CHK1, another CDK-20 
regulating kinase downstream of the ATR and ATM kinases, WEE1 is found to regulate 
DNA replication initiation and nucleotide consumption (5). 
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Given its multiple roles in the DDR programme, targeting WEE1 in cancer has attracted 
much attention. Numerous studies have now shown that WEE1i augments the effect of 25 
DNA-damaging agents, notably gemcitabine (6,7). Owing to the functional overlap 
between WEE1 and CHK1, the current mechanistic paradigm prescribes that WEE1i 
interacts with gemcitabine similarly as CHK1i does. The presumption is that both types 
of inhibition amplify gemcitabine-induced damage via G2-M abrogation, causing 
premature mitosis, mitotic catastrophe and consequently cell death (8,9). Emerging 30 
evidence has also associated WEE1i to aberrant origin firing and nucleotide depletion, 
culminating in phenotypes of replication stress reminiscent of those observed when 
ATR/CHK1 signalling is interrupted (10–13). Despite these conceptual advances, 
several key questions persist. There is considerable ambiguity as to whether WEE1 and 
CHK1 have distinct modulatory effects on the cell cycle, given that co-inhibition of the 35 
two kinases in the absence of a cytotoxic agent yields synergistic effects (14,15). It is 
not without precedent that kinases acting along the same pathway could have 
independent molecular cross-talks that lead to different outcomes when their activity is 
inhibited. For instance, although ATR and CHK1 both coordinate S-phase regulation, 
suppression of ATR triggers a DNA-PK-mediated pathway that reactivates CHK1, but 40 
such compensation is abolished when CHK1 itself is inhibited (16). Moreover, while it is 
evident that WEE1i and CHK1i perturb both S and G2-M checkpoints, the extent of 
these disruptions and how each of them contributes to chemosensitisation remain 
undefined.  
The paucity of mechanistic insights into WEE1i and CHK1i chemosensitisation has 45 
precluded the optimal administration of these inhibitors, even though multiple WEE1i- 
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and CHK1i-based human trials are already underway. Indeed, earlier drug development 
effort has seen attrition of CHK1/2i following unacceptable toxicities in patients (17,18). 
The underlying cause of failure has been attributed to off-target effects than to class 
specificity, suggesting that tolerability issues to these inhibitors are likely to be related to 50 
dose and agent selectivity (19). In the setting of combinations, the challenge of dose-
limiting toxicities becomes more prominent. When combined with chemotherapy, WEE1i 
multiple-dose regimen was more likely to induce toxicities in patients than WEE1i 
single-dose regimen (20). Likewise, gemcitabine plus CHK1i increased the frequency 
and severity of adverse effects in patients beyond what would be anticipated with 55 
gemcitabine alone (21). Previous work by us and others have shown that the 
combination of gemcitabine and CHK1i could be synergistic at low doses (11,22). This 
proposition has now been reinforced by early data demonstrating durable patient 
response following treatment of CHK1i and gemcitabine at a dose that was several 
times lower than the standard (23). Nevertheless, it remains debatable how these 60 
kinase inhibitors should be deployed as combinations. Based on earlier studies that 
presuppose G2-M abrogation as the mechanism of chemosensitisation, CHK1i and 
WEE1i are to be given sequentially after and not concurrently with DNA-damaging 
agents (24,25). Many trials have adopted similar approaches of staggered 
administration, but the outcome for CHK1i thus far has been modest at most (26,27). 65 
Taken together, there is a need to establish optimal dosing schedules for these agents 
before they could be confidently inducted into the clinic.  
We hypothesised that a mechanism-based approach to optimising the doses and 
schedules of cell cycle checkpoint inhibitors with chemotherapy could facilitate the 
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development of more tolerable and effective multitherapeutic strategies. To this end, we 70 
sought to build a comparative mechanistic framework of WEE1i and CHK1i in the 
context of gemcitabine sensitisation. Because gemcitabine is a major component of the 
standard treatment for pancreatic ductal adenocarcinoma, against which few targeted 
agents have been successfully used, we focused our investigation on preclinical models 
of pancreatic cancer. Through the concerted application of mathematical modelling and 75 
single-cell analyses, our effort uncovered important distinctions in cell cycle kinetics 
between WEE1i and CHK1i, leading to the rational implementation of a triple-agent 
schedule capable of inducing cancer-specific lethality at minimally bioactive single-
agent doses.   
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MATERIALS AND METHODS 80 
Cell lines and chemicals 
All human pancreatic ductal adenocarcinoma lines were obtained from either the 
European Collection of Cell Cultures or the American Type Culture Collection, 
authenticated using either Promega GenePrint10 system or Promega PowerPlex 16HS 
kit. MIA PaCa-2 FastFUCCI cell line was generated as previously described (28). 85 
Murine pancreatic ductal adenocarcinoma lines DT8082 and K8484 were established 
from KRasG12D p53R172H Pdx1-Cre mice. All cell lines were routinely verified to be 
mycoplasma-free using the Mycoprobe Mycoplasma Detection Kit (R&D Systems); the 
most recent date of testing was 30 January 2018. All cell lines were used within 20 
passages following thawing in all experiments. 5-bromo-2’-deoxyuridine (BrdU, Sigma), 90 
CHIR124 (Selleck Chemicals), gemcitabine (Tocris), MK1775 (Selleck Chemicals), 
MK8776 (Selleck Chemicals) and roscovitine (Sigma) were dissolved in 
dimethylsulphoxide (DMSO, Sigma) in aliquots of 10-30 mM as stocks. Final DMSO 
concentrations were kept constant (≤0.2%) in all experiments.  
Cytotoxicity and clonogenic assays 95 
For cytotoxicity assays, cells were seeded in 96-well black-walled plates. After 24 hours, 
cells were treated with a serial dilution of specified agents in an 8X8 concentration 
format, with an extra plate fixed at the time of dosing to determine the T0 value. After 
specified days, cells were fixed with trichloroacetic acid and stained with sulforhodamine 
B. Fluorescent readout was evaluated using the Infinite 200 PRO microplate reader 100 
(Tecan) at excitation and emission wavelengths of 488 nm and 585 nm, respectively. 
The T0 value was subtracted from all wells, and growth inhibition was calculated by 
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expressing it as a ratio of the mean of vehicle control wells. Synergy score was 
determined as previously described (11). For clonogenic assays, equal number of viable 
cells were plated 24 hours prior to treatment. After the specified treatment schedule, 105 
cells were fixed with 70% methanol and stained with 0.2% crystal violet (Sigma). 
Colonies were imaged and quantified using GelCount colony counter (Oxford Optronix). 
IncuCyte time-lapse imaging 
Images were taken with the IncuCyte Live Cell Imaging microscopy (Essen Bioscience) 
at every three hours under cell culture conditions with 10-20X objective. Cell confluence 110 
was averaged from multiple fields of view per well. Relative confluence values were 
calculated by normalising each value to the time zero (T0) value. 
Quantitative fluorescence-based microscopy 
Images of fluorescently labelled samples were acquired using the iCys laser scanning 
cytometer (CompuCyte) (40X objective) equipped with a motorised Olympus IX71 115 
inverted fluorescence microscope, three lasers (405 nm violet diode laser, 488 nm 
argon laser, 633 nm helium-neon laser) and three optical filter sets (blue 450/40, green 
530/30, far-red 650LP) coupled to photomultiplier (PMT). The in-built iCys software was 
used to analyse the acquired images. Overlap-proportional Venn diagrams were drawn 
with the Venn diagram plotter software from Pacific Northwest National Laboratory 120 
(http://omics.pnl.gov/). 
FastFUCCI imaging 
The FastFUCCI live-cell assay was performed as previously described (28). Briefly, 
cells were seeded in glass bottom chamber (ibidi GmbH) and were kept under cell 
culture conditions. Images were retrieved using a Nikon Eclipse TE2000-E microscope 125 
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with a 20X long-working distance dry objective and a sCMOS Andor Neo camera. Red 
and green fluorescence were acquired using a pE-300white CoolLED source of light 
filtered by Nikon FITC B-2E/C and TRITC G-2E/C filter cubes, respectively. Live-cell 
time-lapse sequences were split into single channel sequences, and were applied with 
background subtraction and shading correction. Cell-tracking analysis was performed 130 
using the TrackMate plug-in available in the Fiji package. 
Immunostaining and immunoblotting 
For immunostaining, cells seeded in glass bottom chamber (ibidi GmbH) were fixed with 
4% paraformaldehyde, stained with antibodies and counterstained with 4’,6-diamidino-
2-phenylindole (DAPI). 5-ethynyl-2’-deoxyuridine (EdU) Click-it assay was performed 135 
according to manufacturer’s instructions (Life Technologies). For immunoblotting, 
whole-cell extracts were lysed using radioimmunoprecipitation assay (RIPA) buffer (50 
mM Tris pH8, 2 mM EDTA, 150 mM sodium chloride, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate). Protein concentrations were quantified by 
the Bio-Rad Protein Assay (Bio-Rad). Equal amounts of protein were resolved using the 140 
SDS-PAGE gel system (Life Technologies) and transferred to nitrocellulose membranes 
using the iBlot Dry Blotting System (Thermo Fisher Scientific). Blots were blocked with 
Odyssey blocking buffer (LICOR), stained with primary and secondary antibodies, and 
analysed using the Odyssey Infrared Imaging System (LICOR).  
Antibodies 145 
Primary antibodies used were from Cell Signalling unless otherwise mentioned: β-actin 
(Abcam #ab6276), BrdU (BD Pharmingen #555627), cleaved caspase 3 (#9664), CDK1 
(Abcam #ab18), CDK1 Y15 (#9111), CHK1 (#2360), CHK1 S296 (#2349), CHK1 S345 
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(#2348), ENT1 (Abcam #ab135756), H2AX (#7631), H2AX S139 (Millipore #05-636), 
H3 (#9715) and H3 S10 (#3377). For secondary antibodies, Alexa 488 (#4408, #4412) 150 
and Alexa 647 (#4410, #4414) from Cell Signalling were used in immunostaining. 
IRDye800-conjugated (#925-32210, #926-33210) and IR680-conjugated (#926-68070, 
#926-68021) antibodies from LICOR were used in immunoblotting.  
Mouse studies 
All mouse experiments were carried out in the CRUK Cambridge Institute Biological 155 
Resources Unit, in accordance with the UK Animals (Scientific Procedures) Act 1986, 
with approval from the CRUK Cambridge Institute Animal Ethical Review and Welfare 
Body. Subcutaneous xenografts of MIA PaCa-2 cells were conceived by implanting 
5X106 cells in 50% Matrigel/50% PBS, in the right flank of 6-10 weeks’ old female 
BALB/c nude mice (Charles River Laboratories). For efficacy study, mice with 160 
established tumour (~300 mm3) were randomised into three per group and treated 
accordingly. Gemcitabine (LKT Laboratories) and MK8776 (Selleck Chemicals) were 
co-dissolved in 20% hydroxypropyl-β-cyclodextrin (Vehicle I, Sigma) and were given to 
mice at 50 mg/kg intraperitoneally. MK1775 (Selleck Chemicals) was dissolved in 0.5% 
methylcellulose (Vehicle II, Sigma) and were given to mice at 60 mg/kg by oral gavage. 165 
For each weekly cycle in the efficacy study, Vehicle I or agents (gemcitabine, MK8776) 
were given first followed 4 hours later by Vehicle II or MK1775, on Day 0 and Day 3. 
Mice were killed once the averaged tumour size quadrupled (~1200 mm3). For analysis, 
the normalised average of the tumour size per group during treatment phase was 
modelled by means of a mixed model, with treatment groups and time (polynomial of 170 
degree 2) as predictors in the fixed part of the model. The within-mouse and time 
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dependences were taken into account by means of random intercept and slopes as well 
as a moving average for the within-mouse residuals. Model checks and sensitivity 
analyses suggested a good model fit. Restricted maximum likelihood estimates, 
standard errors, as well as the degrees of freedom, t-values and p-values of the 175 
corresponding significance test for all fixed effect parameters were calculated. 
Quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS)  
Snap-frozen tumour tissue was homogenised in ice-cold acetonitrile (50% v/v containing 
tetrahydrouridine) using a Precellys 24 homogeniser (Bertin Technologies). An aliquot 
(50 µL) of the homogenate was transferred to a clean tube containing 150 µL of ice-cold 180 
acetonitrile (50% v/v containing internal standards CTP−13C,15N2 from Sigma and dFdC-
13C,15N2 from Toronto Research Chemicals) followed by centrifugation at 21000 G for 
20 minutes. The supernatant was transferred to a clean tube and evaporated to dryness 
under air. The residue was resuspended in water and 15 µL was injected into the mass 
spectrometer. For plasma samples, 25 µL was added to 150 µL of ice-cold acetonitrile 185 
(85% v/v containing internal standard dFdC-13C,15N2) and the mix was processed as 
described for tissue homogenate. Chromatography was performed using an Accela 
pump (Thermo Fisher Scientific) and the analytes were separated on a PGC Hypercarb 
column (100 X 2.1 mm ID, 5 µm; Thermo Fisher Scientific) fitted with a guard column 
(Hypercarb 10 X 2.1 mm, 5 µm; Thermo Fisher Scientific) with (A) 10 mM ammonium 190 
acetate, pH10 and (B) acetonitrile as mobile phases. LC-MS/MS was performed on a 
TSQ Vantage triple stage quadrupole mass spectrometer (Thermo Fisher Scientific) 
fitted with a heated electrospray ionisation (HESI-II) probe operated in positive and 
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negative mode at a spray voltage of 2.5 KV, capillary temperature of 150ºC. Data 
acquisition was performed using LC Quan2.5.6 (Thermo Fisher Scientific). 195 
Immunohistochemistry 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections of 
tumour after heat-induced epitope retrieval by sodium citrate at 100°C for 10-20 
minutes, using Bond Polymer Refine Detection kit on the automated Bond system 
according to manufacturer’s instructions (Leica). Pre-staining dewaxing and rehydration, 200 
as well as post-staining dehydration and clearing, were performed on Leica ST5020 
Multistainer. 3,3’-diaminobenzidine (DAB) enhancer (Leica) was applied to increase 
contrast between chromogen-specific staining and the slide background. Slides were 
mounted using Leica CV5030 Coverslipper Workstation and scanned using a 
ScanScopeXT (Aperio Technologies). Quantification was performed using the 205 
ImageScope (Aperio Technologies). Antibodies used for immunohistochemistry were 
geminin (Novocastra #NCL-L-GEMININ), H2AX S139 (Cell Signalling #9718) and H3 
S10 (Upstate #06-570). 
Statistics 
Data were analysed using GraphPad Prism built-in statistical tests indicated in relevant 210 
figure legends. The following asterisk system for p value was used: *p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001.  
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RESULTS 215 
WEE1i and CHK1i elicit chemosensitivity with different potency  
In human (AsPC-1, Capan-1, HPAF-II, MIA PaCa-2, Panc-1) and murine (DT8082, 
K8484) pancreatic adenocarcinoma cell lines showing different cell doubling times, 
WEE1i (MK1775) demonstrated a ~6-fold range of single-agent sensitivity, with GI50 
from 80±19 nM to 455±28 nM (Fig. S1A). Irrespective of the degree of sensitivity, all 220 
tested cell lines were sensitised to gemcitabine upon WEE1 inhibition (Fig. 1A, S1B-E). 
To analyse the data in pharmacologically meaningful terms, we used two independent 
mathematical models of synergy (Bliss and Loewe) to assess the combination of 
gemcitabine and MK1775 across a broad range of concentrations (Fig. 1A). 
Consistently, both models identified a synergistic interaction between the two agents. 225 
However, when we compared gemcitabine+WEE1i synergy metrics to those of 
gemcitabine+CHK1i (MK8776), we found that non-inhibitory concentrations (<GI10) of 
CHK1i with 10-30 nM gemcitabine achieved greater synergy scores than equipotent 
single-agent concentrations of WEE1i (Fig. 1A). The same conclusion was reached with 
the use of two other structurally distinct CHK1-specific inhibitors, CHIR124 and S1181, 230 
suggesting that the differential synergism was not due to off-target effects (11). To 
further substantiate these findings, we tested the combinations on a more gemcitabine-
resistant cell line Panc-1, again demonstrating that CHK1i elicited greater synergistic 
inhibition with gemcitabine than WEE1i at non-inhibitory concentrations (Fig. S1E). 
Crucially, at equivalent inhibitory concentration ratios (Fig. S1E), long-term clonogenic 235 
assays show similar extents of growth inhibition in both gemcitabine+WEE1i and 
gemcitabine+CHK1i, establishing in each instance a bona fide synergy that was durable 
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(Fig. 1B). Together, these data demonstrate that, while WEE1i and CHK1i induce 
gemcitabine hypersensitivity, there exists a disparity in synergy potential where CHK1i 
chemosensitises cells more effectively than WEE1i when given concurrently with 240 
gemcitabine. 
WEE1i invokes two forms of DNA damage with gemcitabine 
WEE1i is commonly presumed to deregulate the DNA replication apparatus in a similar 
manner as CHK1i. To test this notion, we exposed MIA PaCa-2 cells to the minimum 
synergistic concentration of WEE1i (300 nM MK1775) and CHK1i (1 µM MK8776) with 245 
10 nM gemcitabine that elicited equivalent growth inhibition, as derived from their 
respective synergy metrics (Fig. 1A). Notably, these concentrations were clinically 
attainable and tolerable in humans (20,29,30). While gemcitabine alone induced a 
marginal increase in S-phase fraction, both WEE1i and CHK1i with gemcitabine caused 
robust S/G2 accumulation (Fig. S1F). Activation of the CDK members promotes DNA 250 
replication origin firing. Accordingly, suppression of origin firing with a broad CDK 
inhibitor roscovitine partially reversed growth inhibition by gemcitabine+WEE1i and 
gemcitabine+CHK1i (Fig. S1G) (11). However, as opposed to other deoxynucleotides, 
supplementation of deoxycytidine alone, which antagonises gemcitabine by competing 
for incorporation into DNA, was sufficient to rescue proliferation in both combinations 255 
(Fig. S1H-I). These findings indicate that, although nucleotide exhaustion induced by 
WEE1i and CHK1i has frequently been reported as the cause of gemcitabine 
sensitisation, at synergistic concentrations, increased gemcitabine incorporation 
following aberrant origin firing represents the predominant source of replication stress. 
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The differences in replication perturbation by WEE1i and CHK1i, if any, could be 260 
masked by bulk responses of cell population. To address this limitation, we turned to 
measuring molecular markers of genomic stress and damage in each individual cell. 
Exposure to gemcitabine+WEE1i and gemcitabine+CHK1i for 24 hours induced 
comparable levels of RPA32 S4/8 and γH2AX with few (<5%) cleaved caspase-3-
positive cells, establishing a correlation between extensive replication stress (RPA32 265 
S4/8) and apoptosis-independent DNA damage (γH2AX without substantial cleaved 
caspase-3) (Fig. 1C, S1J). However, while the expression of these markers was 
comparable in the combinations, quantitative single-cell analysis reveals that cells 
exposed to WEE1i alone harboured significantly higher levels of γH2AX compared to 
CHK1i (Fig. 1C, S1K). No difference in replication stress levels as measured by 270 
hyperphosphorylated RPA32 was found between these two conditions. Furthermore, a 
significantly lower fraction (54±5%) of the damaged population exposed to 
gemcitabine+WEE1i featured replication stress, in contrast to the 72±3% in 
gemcitabine+CHK1i (Fig. 1D). Together, these data suggest that the genomic damage 
created by WEE1i in the presence of gemcitabine could evolve from replication stress-275 
dependent and -independent routes, raising a key question on how these effects are 
manifested in each phase of the cell cycle. 
Passage through mitosis underlies WEE1i chemosensitisation 
The above findings implied a biological consequence of WEE1 inhibition that was 
distinct from replication deregulation. To pursue this hypothesis, we first quantified the 280 
cell cycle durations using the live single-cell FastFUCCI assay (28). Compared to 
vehicle and WEE1i-only conditions, synergistic 10 nM gemcitabine+300 nM WEE1i 
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resulted in an increase in mean S/G2 residence time (Fig. 2A). However, the increase in 
S/G2 duration induced by 10 nM gemcitabine+300 nM WEE1i did not differ from that by 
10 nM gemcitabine alone. In contrast, mean S/G2 duration was longer with synergistic 285 
concentrations of gemcitabine+CHK1i than with 10 nM gemcitabine (Fig. 2B). This 
disparity was in spite of both combinations prolonging G1 to an extent that was as much 
as that in high (100 nM) concentration of gemcitabine (Fig. S2A-B). Notably, both 
WEE1i and CHK1i partially abrogated the S/G2 prolongation induced by 100 nM 
gemcitabine (Fig. 2A-B), in agreement with the concentration-dependent model of G2-M 290 
abrogation (11). Together, the data reveal differential cell cycle timing effects by WEE1i 
and CHK1i at synergistic concentrations with gemcitabine, even though the ultimate 
consequence is a delay in S/G2 (Fig. S1F). 
The integrity of S/G2 and mitosis are dynamically linked across cell generations (31). To 
systematically deconstruct this biological flux, we measured the duration of each cell 295 
cycle stage of first- and second-generation cells following gemcitabine+WEE1i. 
Surprisingly, despite the collective delay in S/G2 phase (Fig. 2A, S1F), the S/G2 phase 
of first-generation cells in the treated sample was comparable with that in control, 
suggesting an initial reprieve of S/G2 impediment (Fig. 2C, S2C). This observation was 
in contrast to CHK1i, which could prolong the S/G2 residence time as much as two folds 300 
in the first cycle (11). Upon entering mitosis, mitotic duration in the gemcitabine+WEE1i-
treated cohort was more than three times longer than control (Fig. 2C, S2C). All 
subsequent cell cycle stages in the treated sample were also significantly protracted. To 
interpret these spatiotemporal details in the context of cellular responses, we tracked 
the fate evolution of gemcitabine+WEE1i-treated cells using three approaches. First, 305 
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quantification of individual cell fates shows that (1) the majority of non-division events in 
the first cycle arose during or after mitosis (47% cytokinesis failure and 33% mitotic 
death, compared to 20% death in S/G2), and that (2) the incidence of non-division 
escalated from 30% in the first cycle to 78% in the second cycle (Fig. 2D). Second, 
cross-generation analysis indicates that (1) 75% of second-generation cells arising from 310 
productive first-generation cells subsequently experienced a deleterious event 
(cytokinesis failure, cell cycle arrest, cell death), but (2) all unproductive first-generation 
cells (i.e. those that underwent cytokinesis failure) were again unproductive in the 
second cycle (Fig. S2D). Third, pairwise sister cell examination reveals that (1) a 
productive sister did not necessarily predict a productive counterpart, but (2) if one of 315 
the sisters was unproductive, the other sister tended to share the same fate (Fig. S2E). 
Together, these data demonstrate that WEE1i chemosensitisation is most profound only 
after a cell launches into its first mitosis, with deleterious events occurring during or after 
mitosis and persisting over generations. 
WEE1i effects on cell cycle kinetics are temporally coordinated 320 
Abrogation of G2-M checkpoint is frequently regarded as the mechanism of WEE1i and 
CHK1i, but precisely when and in which cell cycle stage the event could arise are 
unknown. We previously showed that CHK1i at synergistic concentrations with 
gemcitabine in fact did not effectively override G2-M checkpoint (11). In contrast, 
gemcitabine+WEE1i induced a demonstrable reduction in inactive CDK1 Y15 that 325 
correlated with an increase in mitotic marker H3 S10, suggesting CDK hyperactivation 
and accumulation of mitotic cells (Fig. 3A). Comparative single-cell analysis shows that 
the mitotic DNA content in gemcitabine+WEE1i sample was significantly lower than its 
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single-agent controls and CHK1i, further indicating a mitotic subset with incomplete 
(<4N) genome (Fig. 3B, S3A). As measured by the level of γH2AX, both WEE1i and 330 
CHK1i combinations with gemcitabine invoked comparable degrees of genomic damage 
in S/G2/M cells (Fig. S3B). However, quantitative immunofluorescence shows that 
WEE1i alone induced greater genomic damage in the mitotic fraction than CHK1i alone. 
This difference was particularly pronounced when WEE1i was combined with 
gemcitabine, where 95% of mitotic cells exhibited dramatic DNA fragmentation 335 
decorated with intense γH2AX, compared to 60% in gemcitabine+CHK1i (Fig. S3B). 
Collectively, these data illustrate the superiority of WEE1i over CHK1i in driving cancer 
cells into stressful mitotic states. 
The persistent presence of a mitotic subset with normal 4N DNA under WEE1i 
conditions suggested that not all affected cells were compelled into mitosis directly from 340 
S phase (Fig. S3C). To resolve how WEE1i impacted the S and mitotic phases, we 
segregated asynchronous cell population into early, mid and late S phases as well as 
mitosis using quantitative multiparametric image-based cytometry. Acute WEE1 
inhibition for 1 hour delayed mitotic progression but drove a fraction of only late S-phase 
cells into mitosis (Fig. 3C, S3D). Simultaneously, about 1 in every 3 cells in mid and late 345 
S phase compartments experienced DNA damage (Fig. 3D, S3E). Co-staining of H3 
S10 and native BrdU confirms that mitotic accumulation started within 1 hour; however, 
it was after this timepoint that single-stranded DNA (ssDNA) became evident in the 
mitotic population (Fig. 3E-F, S3F). Notably, ~40-50% of <4N premature mitotic cells 
harboured ssDNA at 4 and 8 hours following treatment, suggesting that these cells were 350 
under-replicated and may still be replicating (Fig. S3F). Pulse labelling with EdU 
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indicates that there was indeed active DNA synthesis predominantly in late-S and 
prophase cells, in line with stress-triggered mitotic DNA replication (Fig. S3G) (32). 
Within the same timeframe, there was neither mitotic block nor accumulation of ssDNA-
harbouring mitotic cells with CHK1 inhibition, reinforcing the notion that the mitotic 355 
consequences of CHK1i are not acute (Fig. S3H). Together, these data show three 
temporally coordinated but independent responses following WEE1 inhibition: (1) Upon 
initial insult, replication stress-independent mitotic block is enacted in mitotically 
competent (4N) cells. (2) Concurrently, a fraction of mid to late S-phase cells encounter 
genomic damage. (3) At the same time, a subset of late S-phase (<4N) cells 360 
prematurely slip into mitosis. These premature mitotic cells persist to synthesise DNA 
ineffectively, with WEE1i-induced CDK hyperactivation further aggravating the mitotic 
state by delaying its resolution. 
Scheduled gemcitabine/CHK1i/WEE1i sustains tumour cell inhibition  
Our data thus far show that the respective interactions of WEE1i and CHK1i with 365 
gemcitabine are synergistic but differ in several other pharmacological terms (Fig. 4A). 
First, although both inhibitors induce gemcitabine hypersensitivity to equal synergistic 
levels, CHK1i generates greater synergy at equivalent single-agent inhibitory 
concentrations than WEE1i (Fig. 1, S1). Second, although both inhibitors trigger 
replication stress, WEE1i prolongs S/G2 only after the first cell cycle, with catastrophic 370 
events occurring chiefly during or following mitosis, coincident with cross-generation 
damage accruement (Fig. 2, S2). Third, unlike CHK1 inhibition where mitotic distress 
originates from a deregulated replication checkpoint, WEE1i directly affects both mitotic 
entry and progression by potent disinhibition of mitotic CDK (Fig. 3, S3). From a 
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therapeutic perspective, these distinctions are consistent with the reported synergy 375 
between WEE1i and CHK1i (14,15). Furthermore, analysis of two cancer cell line 
databases shows that WEE1 and CHK1 expression were significantly correlated in 
diverse cancer subtypes (Fig. 4B, S4A). In agreement, cell lines with high WEE1 or 
CHK1 expression were more sensitive to a WEE1/CHK1 dual inhibitor 681640, but such 
association was less robust in a CHK1/2-specific inhibitor AZD7762, arguing from a 380 
genetic perspective the advantage of co-targeting the two kinases (Fig. S4B) (33). 
Importantly, the trend of a positive correlation between WEE1 and CHK1 expression 
was also observed in multiple patient samples of different tumour origins (Fig. S4C). In 
primary pancreatic ductal adenocarcinoma, high expression of these kinases was a 
strong determinant of poor overall survival and disease-free survival (Fig. 4C, S4D). 385 
Equally, overexpression of these kinases was associated with shorter overall survival in 
three other aggressive tumours, including lung adenocarcinoma where gemcitabine is 
also used routinely. Together, these findings offer a compelling rationale to combine 
WEE1i with CHK1i to maximise gemcitabine sensitivity.  
To determine optimal dosing schedules for WEE1i and CHK1i with gemcitabine, we 390 
used real-time in vitro imaging and found that delayed administration of CHK1i at 24 
hours relative to gemcitabine did not lead to substantial growth inhibition (Fig. 4D). 
Conversely, concurrent administration yielded dramatic growth suppression, even when 
gemcitabine and CHK1i were removed after 24 hours. Given that G2-M abrogation was 
not the predominant mechanism of synergy for gemcitabine+CHK1i, we hypothesised 395 
that the combination could be further enhanced by driving G2-M bypass using WEE1i. 
We determined the growth kinetics of MIA PaCa-2 cells exposed to the schedule of 
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gemcitabine+CHK1i (MK8776 or CHIR124) for 24 hours followed by WEE1i (Fig. 4E). 
Cell growth inhibition was remarkably durable with the triple regimen compared to 
vehicle and dual agent controls. Notably, substitution of WEE1i in the triple regimen with 400 
another CHK1i (i.e. gemcitabine+MK8776 followed by CHIR124, or 
gemcitabine+CHIR124 followed by MK8776) failed to recapitulate the durable response. 
Long-term clonogenic assays confirm effective growth suppression of the proposed 
triple regimen and further show that administering gemcitabine+CHK1i followed by 
WEE1i was more effective than administering gemcitabine+WEE1i followed by CHK1i 405 
(Fig. S4E-F). Together, the sequence-dependent cooperativity of WEE1i with 
gemcitabine+CHK1i validates the differential mechanistic properties of WEE1i and 
CHK1i, affirms the lethality of G2-M bypass, and demonstrates the antitumour potential 
of the proposed triple regimen. 
In vivo studies show antitumour potential of minimal-dose multitherapy 410 
To evaluate whether the in vitro mechanistic findings could be recapitulated in vivo, we 
chose a low dose of gemcitabine (25 mg/kg) compared to the “full” maximum tolerable 
dose (MTD) dose (100-150 mg/kg) administered to mice bearing MIA PaCa-2 
xenografts. An intraperitoneal bolus of 25 mg/kg MK8776 increased gemcitabine-
induced CHK1 S345 phosphorylation and abrogated CHK1 S296 autophosphorylation 415 
for at least the first four hours, indicating target engagement (Fig. S5A-B). These 
changes were accompanied by an increase in γH2AX and RPA32 S4/8 without overt 
CDK1 hyperactivation or H3 S10 upregulation, consistent with the lack of G2-M 
checkpoint bypass we previously established with CHK1i S1181 (Fig. 5A, S5B-C) (11). 
Quantitative immunohistochemistry further confirms high genomic damage and low 420 
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mitotic index with aberrant mitoses in the combination cohort (Fig. 5B, S5D-E). 
Moreover, gemcitabine+MK8776 induced an accumulation of geminin-positive cells by 8 
hours, indicative of high S/G2 fraction as observed in cell lines (Fig. 5C). This 
accumulation was in concert with intratumoral elevation of active gemcitabine 
metabolite 2’,2’-difluoro-2’-deoxycytidine triphosphate (dFdCTP) (Fig. 5D). MK8776 did 425 
not significantly alter the pharmacokinetics of native gemcitabine (2’,2’-difluoro-2’-
deoxycytidine, dFdC) in tumour and in plasma, implying that there was neither 
increased drug uptake in tumour nor decreased drug clearance in blood (Fig. S5F). 
There was also no obvious difference between both treatment arms in the expression of 
a major gemcitabine transporter ENT1 (Fig. S5B-C). Having determined that acute 430 
administration of low gemcitabine and MK8776 in mice induced molecular responses 
observed in vitro, we tested the efficacy of the proposed triple schedule. For stringent 
comparison, we employed doses and treatment frequencies that were equal to or lower 
than those previously established to be suboptimal in MIA PaCa-2 xenograft model, 
which typically exhibits marginal response even to the highest doses of gemcitabine 435 
combinations (34–37). As the in vitro findings predicted, the triple minimal-dose regimen 
was most effective in the growth suppression of established (~300 mm3) tumours 
compared to single- and double-agent arms (Fig. 5E). During the treatment phase (day 
0 to 26), the triple regimen was the only group that trended towards a difference from 
the vehicle group in terms of tumour volume (p = 0.04 by t-test, p = 0.08 by Dunnett’s 440 
multiple-comparison test). Following the treatment phase, the regimen delayed tumour 
growth by about 10 days relative to control, before the averaged tumour size 
quadrupled. Importantly, there was no overt weight loss in mice treated with the triple 
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combination, suggesting that the regimen did not impact physiological functions at least 
within the period of investigation (Fig. S5G). Together, the in vivo data support the in 445 
vitro mechanistic findings and demonstrate the underappreciated feasibility of minimal-
dose multitherapy in achieving tumour control.   
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DISCUSSION 
Targeting cancer with cell cycle checkpoint inhibitors in combination with chemotherapy 
is conceptually attractive, but the success has thus far been largely dependent on 450 
serendipity (38,39). Here, we used a mechanism-guided approach to systematically 
combine classic cytotoxic agent gemcitabine with two DDR clinical candidates CHK1i 
and WEE1i. We first established synergy between pairs of these agents through 
mathematical modelling of individual dose-response curves, simultaneously identifying 
the concentration ratios that yielded optimal growth inhibition. From a series of single-455 
cell studies conducted at these synergistic ratios, we uncovered distinct cell cycle 
kinetics between CHK1i and WEE1i, contrary to the common presumption that these 
inhibitors affect the cell cycle similarly. Notably, upon initial exposure, CHK1i induced S-
phase deregulation in cells more readily than WEE1i, which itself had more direct 
inimical effects on mitosis. Based on these distinctions, we devised a minimal-dose 460 
gemcitabine/CHK1i/WEE1i triple regimen that achieved tumour control without 
additional toxicity. 
Our work represents a preclinical proof-of-concept that MTD is not necessarily the best 
approach in developing multitherapeutic regimens. To date, most clinical studies use 
MTD as a standard for dose selection of chemotherapy. This paradigm stems from 465 
historical observations that response to cytotoxic agents often correlates with dose. 
Recent advances in tumour evolution have begun to question the basis of MTD, given 
the potential rapid expansion of resistant clones from intensive drug-induced selection 
(40,41). The advent of targeted therapies, which unlike cytotoxic drugs exploit cancer-
specific features, has also challenged the relevance of MTD (42). In one instance, meta-470 
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analysis of 24 clinical trials shows similar outcomes between patients treated with low- 
and high-dose targeted agents, with the latter cohorts having higher dropout rates due 
to cumulative toxicities (43). These findings were supported by another study 
demonstrating through computational modelling that drug concentrations lower than the 
MTD could be equally efficacious (44). The complexity of identifying optimal doses 475 
escalates in the context of drug combinations, where their clinical benefits are tempered 
by further risks of off-target effects. Evidently, drug-specific dose-response kinetics and 
dose-dependent drug effects are formidable challenges in the design of multitherapy, 
and preclinical drug development should be primed to address these considerations 
from the outset. 480 
An immediate clinical impact of our study is the re-evaluation of current schedules used 
in human trials for CHK1i and WEE1i. We demonstrate that concurrent, not sequential, 
treatment of gemcitabine and CHK1i leads to better tumour cell inhibition. This inhibition 
is further enhanced by subsequent addition of WEE1i and not continuation of CHK1i. 
Our proposal is grounded on the mechanisms of synergy we identified at optimal 485 
concentration ratios (Fig. 6). Synergy between gemcitabine and CHK1i relies chiefly on 
the collapse of the S-phase replication checkpoint (11). Higher concentrations of either 
agents induce G2-M bypass as a secondary mechanism, but inherent to these 
scenarios is a greater risk of toxicity, as has been clinically observed (17,21). 
Introduction of WEE1i, which we have determined to be a much superior G2-M 490 
abrogator and mitotic stressor, expands the synergy space of the dual therapy through 
its complementary but independent modes of action. Because this triple regimen 
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rationally staggers the kinase inhibitors with all agents titrated at minimally bioactive 
doses, it should in principle strike a balance between therapeutic activity and tolerability.  
The finding that the low-dose triple regimen can indeed confer tumour suppression 495 
without acute toxicity in mice warrants further exploration. A proximate extension of this 
tripartite DDR model is permutations of similarly acting modalities. For instance, 
combinations of radiotherapy with gemcitabine and WEE1i are now entering early-
phase clinical trials (45). Understanding their mechanisms at optimal dose ratios can 
inform decisions on doses, treatment sequences and timing of administration. Equally, 500 
the triple regimen (gemcitabine, CHK1i, WEE1i) or its variant is testable in preclinical 
models tailored to pursuing specific questions on tumour initiation and progression. In 
particular, overcoming the evolution of treatment resistance is a key aspect of invoking 
drug combinations. Therefore, evaluating clinic-pathologic parameters such as long-
term survival, metastasis and disease relapse, as well as understanding the resurgence 505 
of resistance will be crucial to innovating more effective multitherapeutic strategies. The 
same tenet of rationalising multipronged regimens should apply to current treatments in 
the clinic. Already, gemcitabine is being replaced by gemcitabine plus nab-paclitaxel 
and FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin) as the standard of 
care for pancreatic ductal adenocarcinoma, with enthusiasm in further combining them 510 
with immunotherapy (46). There is a need to identify logical ways to induct these 
cocktails, and we anticipate mechanism-led preclinical studies directed at defining 
optimal doses and schedules to be instrumental in this endeavour. Admittedly, the 
scope of these translational works must also be expanded to include the physical and 
biological properties unique to each tumour type. For instance, the heterogeneity in drug 515 
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penetration to target sites and the diversity of the tumour microenvironments are factors 
that could influence treatment outcome in patients. These features can only be 
comprehensively addressed with further development of preclinical tools and models, as 
well as the integration of laboratory discoveries and clinical insights. 
Computational modelling on patients has shown that, while dual therapy confers clinical 520 
benefits, patients with large disease burden require triple therapy (47). There is 
currently no established bioinformatic tools that can predict the interaction of more than 
two therapeutic agents. Our approach obviates this barrier by coupling existing synergy 
metrics with mechanistic reasoning anchored at a single-cell level. This effort, which 
weights efficacy with tolerability, is a distinct component in the emerging trend of using 525 
high-resolution cellular data for the rational design of multitherapy (48,49). The 
implications of these detail-driven translational studies on the next generation of drug 
development could be profound.  
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FIGURE LEGENDS 
Figure 1: WEE1i and CHK1i synergise with gemcitabine with different potency. 
(A) Combination assay. MIA PaCa-2 cells were treated for 72 hours. Data were 
analysed with two synergy mathematical models. Combinations of 10-30 nM GEM with 
a pair of non-inhibitory (<GI10) equivalent concentrations of MK1775 and MK8776 are 
boxed in white. Bar graph shows the mean synergy score within the boxed surface. 
Data are represented as mean ± SEM, n=3. A two-tailed t-test was performed, *p≤0.05. 
(B) Clonogenic assay. Panc-1 cells were treated for 72 hours (30 nM GEM, 300 nM 
MK1775, 1 µM MK8776), and were left to grow after washout for 10 days. Data are 
represented as mean ± SEM, n=3. A one-way ANOVA analysis was performed, 
*p≤0.05, ****p≤0.0001. 
(C) Quantitative immunofluorescence of MIA PaCa-2 cells treated for 24 hours (10 nM 
GEM, 300 nM MK1775, 1 µM MK8776). Each blue, green or red dot marks a cell 
positive for γH2AX, RPA32 S4/8 or both, respectively.  
(D) Quantification of overlap between γH2AX (red) and RPA32 S4/8 (green) in MIA 
PaCa-2 cells treated for 24 hours (10 nM GEM, 300 nM MK1775, 1 µM MK8776). 
Percentage of γH2AX-positive cells in RPA32 S4/8-positive population is in green; 
percentage of RPA32 S4/8-positive cells in γH2AX-positive population is in red. Red 
arrowhead denotes γH2AX-positive cell; yellow arrowhead denotes γH2AX/RPA32 S4/8 
double-positive cell. Data are represented as mean ± SEM, n=5. At least 2000 cells per 
condition per replicate were analysed. A two-tailed t-test was performed, *p≤0.05. Scale 
bar, 25 µm. 
Figure 2: Mitotic stress underlies WEE1i cytotoxicity. 
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(A-B) S/G2 duration of MIA PaCa-2 FastFUCCI cells treated as indicated. At least 100 
cells per condition were analysed. Data are represented as mean ± SEM. A one-way 
ANOVA analysis was performed, ****p≤0.0001. 
(C) Cell cycle duration of MIA PaCa-2 FastFUCCI cells treated with DMSO or 10 nM 
GEM+300 nM MK1775. A total of 243 cells were analysed. Data are represented as 
mean ± SEM. A two-tailed t-test was performed, *p≤0.05, **p≤0.01, ****p≤0.0001. 
(D) Percentage of MIA PaCa-2 FastFUCCI cells in the first and second cycles that 
underwent division or not following 10 nM GEM+300 nM MK1775. Fraction of non-
dividing cells was further categorised according to cell fate. A total of 122 cells were 
analysed. 
Figure 3: Inimical effects of WEE1i are spatiotemporally defined. 
(A) Immunoblotting for MIA PaCa-2 cells treated for 24 hours. The graph shows 
densitometric analysis of CDK1 Y15/CDK1 or H3 S10/H3, relative to DMSO. 
(B) Quantification of DNA content of mitotic MIA PaCa-2 cells treated for 24 hours (10 
nM GEM, 300 nM MK1775, 1 µM MK8776). Data are represented as mean, normalised 
to DMSO. A one-way ANOVA analysis was performed, ****p≤0.0001. 
(C) Quantification of mitotic Panc-1 cells in S phase. Cells were treated with 10 µM EdU 
for 45 minutes followed by 3 µM MK1775 for 1 hour. S and non-S phase cells were 
identified based on EdU and DNA contents. Percentage of H3 S10-positive cells is 
shown.  
(D) Quantification of damaged Panc-1 cells in S phase, treated as in (C). Percentage of 
γH2AX-positive cells is shown.  
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(E-F) Quantification of mitotic Panc-1 cells harbouring ssDNA. Cells were grown with 10 
µM BrdU for 48 hours, treated with 3 µM MK1775 and immunostained for native BrdU. 
In (E), the first column shows positive control, where sample was acid-denatured to 
confirm BrdU incorporation. Scale bar, 10 µm.  In (F), percentage of mitotic cells is in 
black and percentage of native BrdU-positive mitotic cells (out of the respective mitotic 
fractions) in red. At least 2000 cells were analysed per time-point. Inset shows the total 
native BrdU intensity per mitotic cell. A one-way ANOVA analysis was performed, 
****p≤0.0001. 
Figure 4: A gemcitabine/CHK1i/WEE1i regimen enhances tumour cell 
suppression. 
(A) Schematics of the spatiotemporal effects of WEE1i and CHK1i. 
(B) Correlative analysis between WEE1 and CHK1 mRNA expression in 967 tumour cell 
lines from the Cancer Cell Line Encyclopedia project. Pearson correlation coefficient r 
and p values are indicated. 
(C) Kaplan-Meier analysis of RNASeq V2 data on WEE1 or CHK1 expression and 
patient survival in indicated primary tumour samples. Tumours with mRNA expression 
Z-score +1.5 were considered as tumours with high expression. Data were sourced 
from the TCGA Research Network. 
(D-E) Real-time growth kinetics of MIA PaCa-2 cells treated as indicated (10 nM GEM, 
1 µM MK8776, 20 nM CHIR124, 300 nM MK1775). Data are represented as mean ± 
SEM, n=3. 
Figure 5: In vivo studies show antitumour potential of the triple regimen. 
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(A) Quantification of immunoblotting of tumour samples from MIA PaCa-2 xenografts 
treated and harvested as indicated. Data are represented as mean ± SEM, n=3. 
(B) Quantification of immunohistochemistry of tumour samples from (A). γH2AX and H3 
S10 were used as marker of DNA damage and mitosis, respectively. Middle line marks 
the mean. A two-tailed t-test was performed, *p≤0.05. 
(C) Quantification of geminin-positive cells in tumour samples from (A). Data are 
represented as mean ± SEM, n=3. A two-tailed t-test was performed, *p≤0.05. Scale 
bar, 50 µm. 
(D) Pharmacokinetic profile of GEM. Tumour samples from MIA PaCa-2 xenografts 
treated with either 25 mg/kg GEM or 25 mg/kg GEM+MK8776 were analysed for the 
active metabolite of GEM (dFdCTP) at specified time-points. Area under the curve 
(AUC) and p values are indicated. 
(E) Change in tumour volume of MIA PaCa-2 xenografts. Mice were treated as indicated 
for four consecutive weekly cycles. Black triangle on the x-axis denotes start of each 
dosing cycle. Data are represented as mean ± SEM, n=3. 
Figure 6: Combination of GEM, CHK1i and WEE1i maximises synergy space.  
Rationale for GEM/CHK1i/WEE1i triple combination. GEM and CHK1i at optimal non-
cytotoxic concentrations enforces synergy primarily via S-phase deregulation. 
Complementing this combination with WEE1i expands the synergy space of 
GEM+CHK1i by more robust induction of G2 bypass and mitotic stress. 
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